Mechanism of Action: Molecular Level
Dimercaprol (Unithiolum) acts as a specific antidote and serves as an active donor of sulfhydryl (thiol, -SH) groups. Its mechanism is directly tied to the pathogenesis of cardiac glycoside intoxication.
The toxic effect of cardiac glycosides stems from their tight binding to the $Na^+,K^+$-ATPase enzyme in the cardiomyocyte membrane. When administered, Dimercaprol enters a direct chemical reaction with the cardiac glycoside molecule. Because it possesses free thiol groups, the antidote forms strong disulfide bridges with the toxin. Consequently, the glycoside molecule dissociates from the enzyme, liberating the essential thiol groups of $Na^+,K^+$-ATPase required for normal enzymatic function.
Pharmacological Effects and Indications
The key pharmacological effect is the full restoration of $Na^+,K^+$-ATPase transport function. Reactivating this enzyme allows cells to resume active ion exchange, gradually resolving poisoning symptoms.
The primary indication for this drug is specific antidote therapy for complications arising from cardiac glycoside treatment (digitalis toxicity).
Role in Complex Therapy
To successfully manage cardiac glycoside poisoning, Dimercaprol is used as part of combination therapy. It interacts with other treatments as follows:
- Electrolyte replenishment ($K^+$ and $Mg^{2+}$). Once Dimercaprol frees $Na^+,K^+$-ATPase, the enzyme requires activators, specifically magnesium ions. Therefore, potassium chloride or combination products (e.g., Panangin, Asparkam) are co-administered. Magnesium initiates ATPase activity, which is necessary for the active transport of potassium ions into cardiomyocytes.
- Combating calcium overload. To bind (chelate) $Ca^{2+}$ ions in the systemic circulation, edetate disodium (Trilon B) is administered intravenously.
- Correction of conduction disturbances. If atrioventricular (AV) block develops, Atropine is the drug of choice. It blocks cardiac $M_2$ muscarinic receptors, eliminating the vagal inhibitory effect (n. vagus) on the AV node to improve conduction.
Formulations and Dosing Guidelines
The drug is available in two forms:
- Powder (substance).
- 5% solution in 5 mL ampoules.
Routes of administration: subcutaneous (SC), intramuscular (IM), and intravenous (IV). Dosage is calculated strictly based on the patient's body weight. Standard regimen: 1 mL of 5% solution per 10 kg of body weight.
Prescription Examples
Example prescription for a 5% solution ampoule for a 50 kg patient (requires 5 mL, i.e., 1 ampoule per dose):
Rp.: Sol. Unithioli 5% - 5 ml D.t.d. N. 10 in ampull. S. Administer intramuscularly, 5 mL (based on 1 mL per 10 kg of body weight).
Example prescription for powder:
Rp.: Unithioli 1,0 D.t.d. N. 10 S. Follow protocol for solution preparation.